**Roche Announces $50 Billion Expansion of U.S. Operations**
Roche, the Switzerland-based pharmaceutical powerhouse, has unveiled plans to invest $50 billion into its U.S. operations over the next five years. The substantial investment will be directed at expanding and modernizing Roche’s manufacturing and distribution capabilities across the country.
The expansion includes upgrading existing facilities in Kentucky, Indiana, New Jersey, Oregon, and California. Additionally, Roche will construct a new gene therapy manufacturing facility in Pennsylvania, build a continuous glucose monitoring manufacturing plant in Indiana, and establish a new R&D center in Massachusetts. A 900,000-square-foot manufacturing center dedicated to next-generation weight-loss medications is also in the pipeline, with the location yet to be announced.
“Our investments of USD 50 billion over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the U.S. and around the world,” said Thomas Schinecker, CEO of the Roche Group.
Upon completion of these developments, Roche anticipates that it will be exporting more medicines from the U.S. than it imports, significantly strengthening its role in global pharmaceutical production.
*Pictured: Roche’s Genentech campus in San Francisco.*
